Get the Stockscreener App
4.12
2.37%
-0.10
After Hours:
4.13
0.010
+0.24%
X 4 Pharmaceuticals Inc stock is traded at $4.12, with a volume of 438.07K.
It is down -2.37% in the last 24 hours and up +1.98% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$4.22
Open:
$4.22
24h Volume:
438.07K
Relative Volume:
1.08
Market Cap:
$388.60M
Revenue:
$9.01M
Net Income/Loss:
$-99.72M
P/E Ratio:
-0.9079
EPS:
-4.5381
Net Cash Flow:
$-92.85M
1W Performance:
+0.98%
1M Performance:
+1.98%
6M Performance:
+0.49%
1Y Performance:
+54.31%
1-Day Range:
$4.11
$4.425
1-Week Range:
$3.985
$4.425
52-Week Range:
$1.35
$4.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
4.12 | 398.03M | 9.01M | -99.72M | -92.85M | -4.5381 |
VRTX
Vertex Pharmaceuticals Inc
|
466.79 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
612.50 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
903.75 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.41 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
165.81 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Initiated | Guggenheim | Buy |
| Dec-05-25 | Resumed | Stifel | Buy |
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
Form 4 Crinetics Pharmaceuticals Inc For: 22 June By Investing.com - Investing.com Canada
Form 8K Atea Pharmaceuticals Inc For: 22 June By Investing.com - Investing.com Canada
Form 4 Recursion Pharmaceuticals Inc For: 22 June By Investing.com - Investing.com Canada
Form 8K Crinetics Pharmaceuticals Inc For: 22 June By Investing.com - Investing.com Canada
X4 Pharmaceuticals Inc (XFOR) Valuation: PE, PB & Fair Value Analysis - TradingKey
X4 Pharmaceuticals Inc (XFOR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
X4 Pharmaceuticals Inc (XFOR) Institutional Confidence - TradingKey
X4 Pharmaceuticals Inc (XFOR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
X4 Pharmaceuticals Inc (XFOR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
X4 Pharmaceuticals Inc (XFOR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
X4 Pharmaceuticals Inc (XFOR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
X4 Pharmaceuticals Inc (XFOR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
X4 Pharmaceuticals Inc (XFOR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
[Form 4] Tarsus Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Fierce Biotech Layoff Tracker 2026: enGene halves workforce; Neumora cuts 35% - Fierce Biotech
FDA Recalls and Warnings: Gas-X Contaminated With Coolant; More Generic Cymbalta Cancer Risks, Supplements Linked to Salmonella Outbreak - MedShadow Foundation
ALERT: NAFDAC warns Nigerians against contaminated children’s drug recalled in US - TheCable
[Form 4] ARS Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Director-linked funds trim Ligand (LGND) stake with 5,000-share sale - Stock Titan
Layoff Tracker: Genentech R&D cuts include longtime top exec - BioSpace
KalVista (NASDAQ: KALV) director options cashed out, canceled in Chiesi deal - Stock Titan
KalVista (KALV) director closes out 91,000 options in $27-per-share Chiesi merger - Stock Titan
KalVista (KALV) director’s stock options cancelled or cash-settled in Chiesi takeover - Stock Titan
KalVista (NASDAQ: KALV) CMO’s stock, RSUs and options cancelled in $27-per-share Chiesi merger cleanup - Stock Titan
KalVista (KALV) director has 45,000 stock options cashed out in Chiesi merger terms - Stock Titan
KalVista (NASDAQ: KALV) director’s options canceled and cashed out in $27 Chiesi deal - Stock Titan
KalVista (KALV) CCO Sweeny cashes out stock, RSUs and options in Chiesi buyout - Stock Titan
KalVista (NASDAQ: KALV) COO’s RSUs and options cashed out in Chiesi merger - Stock Titan
Chiesi deal cancels options for KalVista (KALV) director Edward Unkart - Stock Titan
KalVista (NASDAQ: KALV) CEO equity cancelled for $27 cash deal - Stock Titan
KalVista (NASDAQ: KALV) CDO disposes equity in $27-per-share Chiesi deal - Stock Titan
KalVista Pharmaceuticals (KALV) CFO exits equity as Chiesi cash deal closes - Stock Titan
Vivo Opportunity entities (INM) add 249,227 InMed shares in open-market buys - Stock Titan
Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings? - TradingView
Supreme Court Clarifies Pleading Standard for Induced Infringement in Hikma v. Amarin - JD Supra
Xenon (XENE) director Patou sells 1,322 shares in tax-related 10b5-1 trade - Stock Titan
Post-bariatric hypoglycemia toll, avexitide trial design at ENDO 2026 - Stock Titan
Cadrenal Therapeutics (CVKD) CEO sells 8,285 shares in planned trades - Stock Titan
Acumen (NASDAQ: ABOS) director equity grant tied to RA Capital funds - Stock Titan
Recursion (NASDAQ: RXRX) director sells 40,000 shares under 10b5-1 plan - Stock Titan
Catalyst Pharmaceuticals (CPRX) CMO gets 3,052 shares, 743 withheld for tax - Stock Titan
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
4 Biotech Stocks Investors Should Watch in 2026 - TradingView
Supreme Court Clarifies Standard for Induced Infringement in Hikma v. Amarin | MintzIntellectual Property Viewpoints - JD Supra
NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology. - markets.businessinsider.com
Recursion (RXRX) director Bumpus sells 4,386 shares under Rule 10b5-1 plan - Stock Titan
Alnylam Pharmaceuticals (ALNY) Partners with Inceptive Nucleics to Enhance Drug Discovery - GuruFocus
ADHD medication shortage reported by pharmaceutical companies - FOX Carolina News
XFOR: Advancing an oral therapy for chronic neutropenia with pivotal data in 2027 and FDA approval targeted for 2028 - TradingView
Justice Jackson Pens Unanimous Decision Backed by SCOTUS Conservatives - Newsweek
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY - TradingView
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
1.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):